生物谷(833266) - 投资者关系活动记录表

Group 1: Investor Relations Activity - The company held an earnings briefing on May 15, 2025, via an online platform, allowing investors to participate remotely [3] - Key personnel present included the Chairman, General Manager, and financial head, indicating a high-level engagement with investors [4] Group 2: Company Strategy and Product Development - The company aims to expand its product line, particularly in the food therapy sector, to enhance revenue and market competitiveness [4] - Current R&D focuses on core products, with a strategy combining independent research and collaboration with other research institutions [5] - The establishment of a Shanghai subsidiary is intended to leverage local advantages for R&D, sales, and talent acquisition [7] Group 3: Market Challenges and Responses - The company faces challenges such as price reductions from national drug procurement and increased competition in certain markets [7] - Strategies to address these challenges include diversifying sales channels, enhancing academic promotion, and optimizing cost structures [7] Group 4: Marketing and Sales Progress - The company has seen sales growth through improved market positioning and digital marketing strategies [9] - Efforts to resolve previous financial issues with the former controlling shareholder are ongoing, with measures in place to mitigate risks [9] Group 5: Future Outlook and Goals - The company plans to deepen its focus on ischemic cardiovascular products and accelerate the development of existing products [9] - There is an emphasis on enhancing product competitiveness through clinical value expansion and collaboration with authoritative institutions [9]